Phathom Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) Transcript
Good morning, everyone, and welcome to the Jefferies Healthcare Conference, day one. We are delighted to have with us the management team of Phathom. And with us today, as you can see, are Terrie Curran, CEO; Azmi Nabulsi, COO. Martin, where are you? There's Martin and he's Head of Sales and Marketing, and Todd Branning, Chief Financial Officer. So, welcome, everyone.
GI-focused Phathom is poised to introduce the next generation agent for managing GI-related disease with a compound called vonoprazan. The initial indications are for the treatment of erosive GERD and H. pylori. HP had very positive data last month, and the GERD data will read out in the coming months, and we have management with us today to get us caught up on progress.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
